eFFECTOR Therapeutics, Inc. announced that its chief medical officer Premal Patel, M.D., Ph.D., has resigned to pursue a new opportunity. Robert Sikorski, M.D., Ph.D., who currently serves as a clinical advisor to the company, will take on an expanded role as senior clinical development advisor while the company conducts an executive search for a new chief medical officer. Dr. Sikorski, who played a similar role for eFFECTOR in 2020, has a deep knowledge of the company's STRI development programs and will lead clinical development of both tomivosertib and zotatifin.

In addition, Dr. Patel will serve as a consultant to eFFECTOR through September 30, 2022. Dr. Sikorski has more than 20 years of clinical development experience and has a long history with the company, having served as a clinical advisor since May 29, 2019, including presenting the tomivosertib Phase 2a results to the FDA in 2020. He is managing director of Woodside Way Ventures, a consulting and investment firm that helps biotechnology companies and investors advance lifesaving technologies through clinical development.